Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 546 results found since Jan 2013.

Implications of COVID-19 to Stroke Medicine: An Epidemiological and Pathophysiological Perspective
Curr Vasc Pharmacol. 2022;20(4):333-340. doi: 10.2174/1570161120666220428101337.ABSTRACTThe neurological complications of Coronavirus 2019 (COVID-19) including stroke have been documented in the recent literature. COVID-19-related inflammation is suggested to contribute to both a hypercoagulable state and haemorrhagic transformation, including in younger individuals. COVID-19 is associated with a heightened risk of ischaemic stroke. Haemorrhagic stroke in COVID-19 patients is associated with increased morbidity and mortality. Cerebral venous sinus thrombosis (CVST) accounts for <1% of stroke cases in the general populat...
Source: Current Vascular Pharmacology - November 3, 2022 Category: Drugs & Pharmacology Authors: Alan King Karen M Doyle Source Type: research

QiShen YiQi and its components attenuate acute thromboembolic stroke and carotid thrombosis by inhibition of CD62P/PSGL-1-mediated platelet-leukocyte aggregate formation
CONCLUSION: QSYQ and YQ/HX components attenuated thromboembolic stroke and carotid thrombosis by decreasing PLA formation via inhibiting CD62P/PSGL-1 expressions. This study shed a new light on the prevention of thromboembolic stroke.PMID:36738500 | DOI:10.1016/j.biopha.2023.114323
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 4, 2023 Category: Drugs & Pharmacology Authors: Mingxing Yu Guangxu Xiao Linhong Han Li Peng Huanyi Wang Shuang He Ming Lyu Yan Zhu Source Type: research

Thrombolytic Agents for Acute Ischaemic Stroke Treatment: the Past, Present and Future.
Abstract Despite advances in the diagnosis and treatment of acute ischaemic stroke in the past two decades, stroke has remained the third cause of mortality and the single leading cause of disability worldwide. The immediate goal of acute ischaemic stroke therapy is to salvage the ischaemic penumbra through recanalisation of the occluded cerebral blood vessel. This is currently achieved through thrombolytics, which are pharmacological agents that can break up a clot blocking the flow of blood. To date, the only approved thrombolytic for treatment of acute ischaemic stroke is recombinant tissue plasminogen activato...
Source: CNS and Neurological Disorders Drug Targets - February 4, 2013 Category: Drugs & Pharmacology Authors: Balami JS, Chen R, Sutherland BA, Buchan AM Tags: CNS Neurol Disord Drug Targets Source Type: research

Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Abstract Atrial fibrillation (AF) confers a 4.5% risk of stroke per year. The risk of stroke increases with various risk factors and until recently, warfarin has been the gold standard of thromboembolism prophylaxis in AF for many years. The dosage of warfarin requires regular adjustment dependent on the INR, to keep within a narrow therapeutic range of 2.0- 3.0. The INR can be altered by concomitant drugs, foods and alcohol and requires inconvenient blood monitoring. Underanticoagulation places patients at risk of stroke, whilst over-anticoagulation confers significant bleeding risk. Consequently approximately ha...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Foley J, Kirchhof P, Lip GY Tags: Curr Vasc Pharmacol Source Type: research

Combination treatment of r-tPA and an optimized human apyrase reduces mortality rate and hemorrhagic transformation 6h after ischemic stroke in aged female rats.
In this study, combination of r-tPA and APT102, a novel form of human apyrase/ADPase, was investigated in a clinically-relevant aged-female rat embolic ischemic stroke model. We propose that successfully extending the therapeutic window of r-tPA administration would represent a significant advance in the treatment of ischemic stroke due to a significant increase in the number of patients eligible for treatment. Results of our study showed significantly reduced mortality from 47% with r-tPA alone to 16% with co-administration of APT102 and r-tPA. Co-administration decreased cortical (47±5% vs. 29±5%), striatal (50±2%, vs...
Source: European Journal of Pharmacology - June 13, 2014 Category: Drugs & Pharmacology Authors: Tan Z, Li X, Turner RC, Logsdon AF, Lucke-Wold B, DiPasquale K, Soeg Jeong S, Chen R, Huber JD, Rosen CL Tags: Eur J Pharmacol Source Type: research

Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Authors: Dzeshka MS, Lip GY Abstract INTRODUCTION: Oral anticoagulation is central to the management of patients with atrial fibrillation (AF) and at least one additional stroke risk factor. For decades, the vitamin K antagonists (e.g. warfarin) remained the only oral anticoagulant available for stroke prevention in AF. The non-vitamin K oral anticoagulants (NOACs) are now available, and these drugs include the direct thrombin inhibitors and factor Xa inhibitors. The latter class includes edoxaban, which has recently been approved for stroke prevention in AF by the United States Food and Drug Administration and the...
Source: Expert Opinion on Pharmacotherapy - February 14, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke
AbstractTirofiban is a non-peptide selective glycoprotein (GP) IIb/IIIa receptor inhibitor that reversibly inhibits fibrinogen-dependent platelet aggregation and subsequent formation of thrombi, which contribute to the major atherosclerotic complications in the development, progression, and resolution of ischemic stroke. The adjunctive use of tirofiban has been extensively evaluated in progressive stroke, combined intravenous thrombolysis (IVT), and endovascular treatment (EVT) in both preclinical and clinical studies. A body of evidence has been accumulated on the risks and benefits associated with tirofiban in terms of p...
Source: Drugs - March 5, 2019 Category: Drugs & Pharmacology Source Type: research

The Tasmanian Atrial Fibrillation Study (TAFS): Differences in Stroke Prevention According to Sex.
Conclusion and Relevance: Female patients with a high stroke risk were less likely to receive guideline-recommended treatment. This study provides new information on prescribing trends within the Australian setting and highlights the opportunity to improve the management of female patients with AF and 1 or more additional stroke risk factors. PMID: 32019321 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - February 3, 2020 Category: Drugs & Pharmacology Authors: Pilcher SM, Alamneh EA, Chalmers L, Bereznicki LR Tags: Ann Pharmacother Source Type: research

Stroke following successful PTMC in a patient with severe mitral stenosis: A case report and presenting a simple stepwise approach to PTMC-related stroke.
We present a middle-aged woman who experienced stroke following PTMC and successfully treated with thrombolytic therapy regarding the potential adverse effects of this type of therapy. Also, we present a simple novel stepwise clinical approach for PTMC-related stroke. PMID: 32077834 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Disorders Drug Targets - February 22, 2020 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Salvianolic acid A prevented cerebrovascular endothelial injury caused by acute ischemic stroke through inhibiting the Src signaling pathway.
In conclusion, our results suggest that SAA protects cerebrovascular endothelial cells against ischemia and OGD injury via suppressing Src signaling pathway. These findings show that pretreatment with SAA is a potential therapeutic strategy for the prevention of ischemic stroke. PMID: 33303991 [PubMed - as supplied by publisher]
Source: Acta Pharmacologica Sinica - December 10, 2020 Category: Drugs & Pharmacology Authors: Liu CD, Liu NN, Zhang S, Ma GD, Yang HG, Kong LL, Du GH Tags: Acta Pharmacol Sin Source Type: research